Trials / Conditions / Prostate Carcinoma Metastatic in the Bone

Prostate Carcinoma Metastatic in the Bone

17 registered clinical trials studyying Prostate Carcinoma Metastatic in the Bone.

Status	Trial	Sponsor	Phase
Withdrawn	Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer NCT03709550	Roswell Park Cancer Institute	Phase 1 / Phase 2
Terminated	ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer NCT04159896	Barbara Ann Karmanos Cancer Institute	Phase 2
Unknown	sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer NCT04033432	Northwestern University	Phase 2
Completed	Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer NCT03751436	Roswell Park Cancer Institute	Phase 1
Active Not Recruiting	Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate C NCT03821792	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small NCT03582475	Jonsson Comprehensive Cancer Center	Phase 1
Active Not Recruiting	Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prosta NCT03344211	University of Southern California	Phase 2
Completed	Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bon NCT03707184	University of Utah	Phase 2
Terminated	Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Pros NCT03442556	University of Washington	Phase 2
Completed	Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate C NCT03406858	Barbara Ann Karmanos Cancer Institute	Phase 2
Active Not Recruiting	Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients W NCT03419234	ECOG-ACRIN Cancer Research Group	Phase 2
Active Not Recruiting	Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced NCT03217747	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Active Not Recruiting	Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Co NCT02713269	M.D. Anderson Cancer Center	Phase 2
Completed	Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containin NCT02598895	University of Washington	Phase 2
Completed	Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prost NCT02555189	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Phase 1 / Phase 2
Terminated	Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-R NCT02215161	University of California, San Francisco	Phase 2
Completed	Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Res NCT01505868	M.D. Anderson Cancer Center	Phase 1 / Phase 2